Interferon-beta treatment for multiple sclerosis (Q36963178)

17 August 2017

1 reference

title

Interferon-beta treatment for multiple sclerosis (English)

1 reference

17 August 2017

0 references

Robert A Bermel

1

1 reference

PubMed ID

17920544

17 August 2017

Richard A Rudick

series ordinal

2

1 reference

17 August 2017

1 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

4

1 reference

17 August 2017

4

1 reference

17 August 2017

633-646

1 reference

https://scigraph.springernature.com/pub.10.1016/j.nurt.2007.07.001

17 August 2017

0 references

cites work

A comprehensive assessment of the cost of multiple sclerosis in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Virus interference. I. The interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

The current status of multiple sclerosis intra-blood-brain-barrier IgG synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

A brief history of the use of interferons as treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Intrathecal interferon in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Development of biomarkers in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Italian studies on early-onset multiple sclerosis: the present and the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Treatment of pediatric multiple sclerosis and variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Managing the adverse effects of interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Liver injury associated with the beta-interferons for MS: a comparison between the three products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Relapses matter: the costs & consequences of multiple sclerosis relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.07.001

Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers

21 January 2018

1 reference

12 December 2020

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

12 December 2020

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Interferon-beta treatment in patients with childhood-onset multiple sclerosis

1 reference

12 December 2020

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

12 December 2020

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

12 December 2020

Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a

1 reference

12 December 2020

Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis

1 reference

12 December 2020

Interferon beta-1a in children with multiple sclerosis is well tolerated

1 reference

12 December 2020

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

The cost of delaying treatment in multiple sclerosis: what is lost is not regained

1 reference

12 December 2020

Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis

1 reference

12 December 2020

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

12 December 2020

Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination

1 reference

12 December 2020

New natural history of interferon-β-treated relapsing multiple sclerosis

1 reference

12 December 2020

Interferon responses of leukocytes in multiple sclerosis

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

12 December 2020

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

12 December 2020

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

1 reference

12 December 2020

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

10.1016/J.NURT.2007.07.001

Identifiers

DOI

1 reference

PubMed ID

17920544

Dimensions Publication ID

17 August 2017

0 references

1 reference

PubMed ID

17920544